Novel immunotherapeutic strategies in gynecologic oncology: Dendritic cell-based immunotherapy for ovarian cancer

Minerva Ginecologica

Volumn 54, Issue 2, 2002, Pages 133-144

  Santin, A D ^a   Bellone, S ^b   Underwood, L J ^b   O'Brien, T J ^b   Ravaggi, A ^b   Pecorelli, S ^b   Cannon, M J ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NONE

Author keywords

Dendritic cells, immunology; Immunotherapy; Ovarian cancer; Ovarian neoplasms, immunology; Ovarian neoplasms, therapy; T lymphocytes, cytotoxic, immunology

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPSIN PROTEIN; HYBRID PROTEIN; LIPOFECTIN; MELAN A; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MONOPHENOL MONOOXYGENASE; PROTEASE M; PUMP 1 PROTEIN; RECOMBINANT PROTEIN; SCCE PROTEIN; SERINE PROTEINASE; TADG 12 PROTEIN; TADG 14 PROTEIN; TADG 15 PROTEIN; TESTISIN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR VACCINE; UNCLASSIFIED DRUG; VIRUS E7 PROTEIN;

ANTIGEN RECOGNITION; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG TARGETING; FOLLOW UP; HOST; HUMAN; IMMUNE RESPONSE; MOLECULAR CLONING; OVARY CANCER; REVIEW; TREATMENT OUTCOME; VACCINATION;

ADULT; ANTIGENS, NEOPLASM; CANCER VACCINES; CHILD; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; KALLIKREINS; MATRIX METALLOPROTEINASE 7; MEMBRANE PROTEINS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; SERINE ENDOPEPTIDASES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0036080196     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Epithelial ovarian cancer
2. Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer
3. Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors
4. Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma
5. Tumor-host interaction: Analysis of cytokines, growth factors, and tumor infiltrating lymphocytes in ovarian carcinomas
6. T cell recognition of human tumors: Implications for molecular immunotherapy of cancer
7. Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: Identification of transforming growth factor β as a suppressive factor
8. Presence of IL-10 in the ascites of patients with ovarian and other intra-abdominal cancers
9. TNF LT, and IL-1 natural inhibitors (soluble receptors and receptor antagonists) in women with ovarian cancer
10. Secretion of vascular endothelial growth factor in ovarian cancer
11. Lymphocytes apoptosis induced by Fas-ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor associated lymphocytes
12. Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells
13. Presentation of renal tumor antigens by human dendritic cells activates tumor infiltrating lymphocytes against autologous tumor: Implications for live kidney cancer vaccines
14. Kinetics of expression of surface antigens during the differentiation of human dendritic cells versus macrophages from monocytes in vitro
15. The DC system and its role in immunogenicity
16. Efficient presentation of soluable antigen by cultured human dendritic cells is maintanined by granulocyte/macrophage colony stimulating factor plus interleukin 4 and down regulated by turner necrosis factor alpha
17. Proliferating dendritic cell progenitors in human blood
18. DCs as adjuvants for class I major histocompatibility complex-restricted antitumor immunity
19. Dendritic cells as adjuvants for immune-mediated resistance to tumors
20. Dendritic cells and the control of immunity
21. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions
22. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
23. + T-cell in humans without foreign helper epitopes
24. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells
25. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
26. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
27. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
28. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
29. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
30. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression
31. Development and therapeutic effect of adoptively transferred T cells primed by tumor lysatepulsed autologous dendritic cells in a patient with metastatic endometrial cancer
32. + cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells in patients with advanced ovarian cancer
33. Induction of T cell responses against autologous ovarian tumors with whole tumor cell lysate-pulsed dendritic cells
34. + cytotoxic T lymphocytes by tumor lysate-pulsed autologous dendritic cells in patients with serous papillary uterine cancer
35. + cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells
36. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity
37. + T cell responses by E7-pulsed autologous dendritic cells in patients with HPV16 and HPV18-positive cervical cancer
38. In vitro stimulation of ovarian tumour-associated lymphocytes with a peptide derived from HER2/neu induces cytotoxicity against autologous tumour
39. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
40. Identification of new HER2/neuderived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas
41. A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals
42. Specific, major histocompatibility-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells
43. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides
44. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin
45. In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors
46. + T cell responses against cancer-associated MUC1 peptide epitopes
47. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies
48. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells
49. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells
50. Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides
51. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers
52. Study of HLA class I restriction and the directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer
53. Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells
54. MAGE, BAGE and GAGE: Tumour antigen expression in benign and malignant ovarian tissue
55. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors
56. Initial immunochemical characterization of MX35 ovarian cancer antigen
57. A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas
58. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers
59. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer
60. The CA125 gene: An extracellular superstructure dominated by repeat sequences
61. Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL-SCID/BG mouse model
62. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody CA125: Immune responses and survival in palliative treatment
63. Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed on ovarian cancer
64. The stratum corneum chymotryptic enzyme which mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells
65. Ovarian tumor cells express a novel multi-domain cell surface serine protease
66. Cloning of TADG-14, a novel serine protease overexpressed by ovarian carcinoma
67. Ovarian tumor cells express a transmembrane serine protease: A potential candidate for early diagnosis and therapeutic intervention
68. Overexpression of testisin, a serine protease expressed by testicular germ cells, in epithelial ovarian tumor cells
69. Increased expression of protease M in ovarian tumors
70. The matrix metalloprotease pump-1 (MMP-7, matrilysin): A candidate marker/target for ovarian cancer detection and treatment
71. Human prostate cancer and benign prostatic hyperplasia. Molecular dissection by gene expression profiling
72. Expression profiling reveals hepsin overexpression in prostate cancer
73. A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer
74. Testisin, a new human serine proteinase expressed by premeiotic testicular germ cells and lost in testicular germ cell tumors
75. A novel protease homolog differentially expressed in breast and ovarian cancer
76. The collagenase gene family in humans consists of at least four members
77. Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumors
78. Expression of metalloproteinase genes in human prostate cancer
79. Expression of MMP-7 (pump-1) mRNA in human colorectal cancers